[拉氧头孢在妇产科领域的实验室及临床研究]

[Laboratory and clinical studies on latamoxef in the field of obstetrics and gynecology].

作者信息

Takase Z, Shirafuji H, Matsuda S, Tanno M, Kashiwakura T, Cho N, Fukunaga K, Kunii K, Hogaki M, Muronosono E, Matsumoto Y, Tabei T, Hayashi S, Nakamura H, Seki K, Fukuda T, Aoyama S, Kurasawa S, Ninomiya K, Hiraoka O, Nakai T, Shimizu H, Sugimoto O, Kamiyoshi S, Watanabe K, Fujimoto A, Doi S, Jujii K, Yamada F, Ozawa M, Shimizu T, Risai T, Morimoto N, Kobayashi H, Kondo I, Saita K, Ibaragi K, Kamigawara Y, Sawaragi I, Yuasa M, Hirabayashi K, Okada E, Shirakawa K, Oniki K, Yamamoto K, Yamabe T, Motomura R, Nakanishi K, Teramoto C, Haraguchi H

出版信息

Jpn J Antibiot. 1983 Jan;36(1):1-15.

PMID:6221127

Abstract

Latamoxef (LMOX) is a new antibiotic synthesized by Shionogi Research Laboratory. Chemically LMOX is especially unique with a sulfur atom replacing the oxygen atom in the 1 position of the conventional cephalosporin nucleus, and in addition, this antibiotic has a cephamycin-like structure. The antibacterial activity of LMOX shows high potency against Gram-negative bacteria, but tends to be weak against Gram-positive bacteria. The tissue levels of LMOX in humans after intravenous injection of 1 g were examined. The levels in uterine and adnexa uteri tissue at 1 hour after administration were 25.4 and 27.4 micrograms/g respectively. LMOX was administered to 147 cases in infections of obstetric and gynecological field. The clinical effect according to disease was 94.6% for intrauterine infections, 95.0% for adnexitis, 87.0% intrapelvic infections, and 100% for external genital organ infections, making a total of 92.5%. The rate of occurrence of side effects or abnormal laboratory findings was similar to or slightly less than that seen with other beta-lactam antibiotics.

摘要

拉氧头孢（LMOX）是盐野义制药研究实验室合成的一种新型抗生素。从化学结构上看，LMOX尤为独特，它在传统头孢菌素核的1位上用硫原子取代了氧原子，此外，这种抗生素还具有头霉素样结构。LMOX的抗菌活性对革兰氏阴性菌显示出高效力，但对革兰氏阳性菌往往较弱。对1克静脉注射后人体中LMOX的组织水平进行了检测。给药后1小时子宫和子宫附件组织中的水平分别为25.4和27.4微克/克。LMOX用于147例妇产科感染病例。根据疾病的临床疗效，子宫内感染为94.6%，附件炎为95.0%，盆腔内感染为87.0%，外生殖器感染为100%，总计为92.5%。副作用或实验室异常结果的发生率与其他β-内酰胺类抗生素相似或略低。